NeOnc shares early glioma data for nasal NEO100; neither pipeline drug is approved
The Nasdaq-listed company's slide deck puts a small, uncontrolled 24-patient study at the centre of its brain-tumour pitch, with no regulatory milestone or deal terms attached.
NeOnc Technologies (NASDAQ: NTHI) has put early clinical results for its intranasal brain-cancer candidate NEO100 at the front of a slide deck dated 18 November 2026. The document also covers NEO212, an oral drug. The deck gives no revenue, partnership or financing details, so the commercial case rests on the clinical data alone.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.